Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Gavi Advance Purchase Agreement- COVAX Facility Gavi Advance Purchase Agreement- COVAX Facility [Member] Gavi Advance Purchase Agreement- COVAX Facility Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Range [Domain] Statistical Measurement [Domain] Creditable against royalties Collaborative Agreement, Upfront Payment Receivable, Amount Creditable Against Royalties Collaborative Agreement, Upfront Payment Receivable, Amount Creditable Against Royalties Title of 12(b) Security Title of 12(b) Security Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Document Fiscal Year Focus Document Fiscal Year Focus Schedule of Fair Value Hierarchy Fair Value Measurements, Nonrecurring [Table Text Block] Net proceeds from the exercise of stock-based awards, net of tax withholding Net Proceeds From The Exercise Of Stock-Based Awards Net Proceeds From The Exercise Of Stock-Based Awards Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Segment Reporting [Abstract] Restructuring Plan [Axis] Restructuring Plan [Axis] Common stock, $0.01 par value, 600,000,000 shares authorized at June 30, 2026 and December 31, 2025; 168,165,416 shares issued and 164,815,529 shares outstanding at June 30, 2026 and 164,969,773 shares issued and 162,575,937 shares outstanding at December 31, 2025 Common Stock, Value, Issued Serum Serum [Member] Serum Schedule of Long Term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Line of Credit Line of Credit [Member] Restatement Determination Date Restatement Determination Date Total licensing, royalties, and other revenue Licensing, Royalties, And Other Revenue Licensing, Royalties, And Other Revenue Provision for excess and obsolete inventory Inventory Write-down Number of shares available for issuance (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available For Issuance Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available For Issuance Grants receivable Grants Receivable Allowance for credit losses Accounts Receivable, Allowance for Credit Loss Amendment Flag Amendment Flag Current liabilities: Liabilities, Current [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Finance lease payments Finance Lease, Principal Payments Transition Services Transition Services [Member] Transition Services Nuvaxovid sales Nuvaxovid Sales [Member] Nuvaxovid Sales Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Schedule of Investments Classified as Available-for-sale Debt Securities, Available-for-Sale [Table Text Block] Upfront fee amortization Upfront Fee Amortization [Member] Upfront Fee Amortization Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Prepayment penalty percentage Debt Instrument, Prepayment Penalty Percentage Debt Instrument, Prepayment Penalty Percentage Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Foreign currency translation adjustment Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value per share (in usd per share) Common Stock, Par or Stated Value Per Share Assets Assets, Fair Value Disclosure [Abstract] Cash and Cash Equivalents [Abstract] Outstanding and Unvested, beginning balance (in shares) Outstanding and Unvested, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Basic (in shares) ​Weighted average number of common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Australia Revenue Agency Member Australia Revenue Agency Member [Member] Australia Revenue Agency Member Deferred revenue Increase (Decrease) in Deferred Revenue Amortized Cost​ Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss Other comprehensive income (loss): Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Entity Address, City or Town Entity Address, City or Town Restricted stock units granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Amount of transaction price not yet satisfied Remaining Performance Obligation, Amount Remaining Performance Obligation, Amount Stock-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Restricted stock units vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Class of Stock [Axis] Class of Stock [Axis] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Product sales Product [Member] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Debt issuance costs Debt Issuance Costs, Gross Interest rate Line of Credit Facility, Interest Rate at Period End Net income (loss), basic Net Income (Loss) Available to Common Stockholders, Basic Percentage increase of shares each anniversary Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase Level 2 Fair Value, Inputs, Level 2 [Member] Other income (expense): Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Tranche 4 Tranche 4 [Member] Tranche 4 Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] United States UNITED STATES Stock-based compensation capitalized Share-Based Payment Arrangement, Amount Capitalized Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Capital expenditures included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Schedule of Segment Reporting Information, by Segment Segment Reporting [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Unsecured Debt Unsecured Debt [Member] Grants, U.S. Government Contract and Joint Venture [Abstract] Grants, U.S. Government Contract and Joint Venture [Abstract] Grants, U.S. Government Contract and Joint Venture Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Direct CIC and influenza vaccines CIC And Influenza Vaccines [Member] CIC And Influenza Vaccines Prepayment Year [Axis] Prepayment Year [Axis] Prepayment Year Stock issued under incentive programs Compensation stock issued under incentive program Value of stock issued issued under incentive programs. Long-term debt Total long-term debt Long-Term Debt Deferred revenue refund Contract With Customer, Liability, Potentially Refundable Contract With Customer, Liability, Potentially Refundable Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities, Current Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Net income (loss) per share: Earnings Per Share, Basic [Abstract] Stockholders' Deficit Equity [Text Block] Expenses: Costs and Expenses [Abstract] Security Exchange Name Security Exchange Name Debt instrument, contractual term Debt Instrument, Term Treasury stock, cost basis, 3,349,887 shares at June 30, 2026 and 2,393,836 shares at December 31, 2025 Treasury Stock, Common, Value Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Net income (loss), dilutive Net Income (Loss) Attributable to Parent, Diluted Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Billed contracts receivable Billed Contracts Receivable Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Earnings per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Unbilled contracts receivable Unbilled Contracts Receivable Net income (loss) per share: Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Takeda Takeda [Member] Takeda Schedule of Product Sales Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Table Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Fair Value​ Fair value Debt Securities, Available-for-Sale, Excluding Accrued Interest Geographical [Domain] Geographical [Domain] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Collaborative agreement, upfront payment amount Collaborative Agreement, Upfront Payment Receivable, Annual Amount Collaborative Agreement, Upfront Payment Receivable, Annual Amount Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] ​Weighted average number of common shares outstanding: Denominator: Weighted Average Number of Shares Outstanding, Basic [Abstract] Company Selected Measure Name Company Selected Measure Name Sale of Stock, Name of Transaction [Domain] Sale of Stock [Domain] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Income Tax Disclosure [Abstract] Amortization and accretion of debt issuance and exit costs Amortization of Debt Issuance Costs and Discounts Accrued Credit Agreement exit fee Debt Instrument, Exit Fee Debt Instrument, Exit Fee Interest rate Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue [Table Text Block] Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue Net unrealized gain (loss) on available-for-sale marketable securities Unrealized gain (loss) on available-for-sale marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Year Three Year Three [Member] Year Three Cash and cash equivalents, restricted cash, and marketable securities Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Discontinued Operation Supplemental disclosure of non-cash activities: Noncash Investing and Financing Items [Abstract] Long term debt, gross Long-Term Debt, Gross Credit Facility [Domain] Credit Facility [Domain] Asset Class [Domain] Asset Class [Domain] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Operating Activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Capitalized contract cost, amortization Capitalized Contract Cost, Amortization Individual: Individual [Axis] Diluted (in shares) ​Weighted average number of common shares outstanding, dilutive (in shares) Weighted Average Number of Shares Outstanding, Diluted Revenue Recognition Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Proceeds from credit facility, net of issuance costs Proceeds from Lines of Credit Right-of-use assets from new lease agreements Non-Cash Related Transactions For Finance Lease, Right-Of-Use Asset Non-Cash Related Transactions For Finance Lease, Right-Of-Use Asset Treasury securities US Treasury Securities [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Loan facility, current available capacity Line of Credit Facility, Current Borrowing Capacity Maximum discount rate Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date Award Timing Predetermined Award Timing Predetermined [Flag] Capital expenditures, including internal-use software Payments for Capital Improvements Treasury Stock Treasury Stock, Common [Member] Schedule of Interest Expense Interest Expense Related to Long Term Debt [Table Text Block] Tabular disclosure of interest expense related to convertible notes. Intangible Asset, Goodwill and Other [Abstract] Intangible Asset, Goodwill and Other [Abstract] Aggregate intrinsic value, stock options and vesting RSA's Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Marketable Securities Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Severance and employee benefit costs Severance Costs Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Upfront fee and milestones Upfront Fee And Milestones Upfront Fee And Milestones 2023 Restructuring Plan 2023 Restructuring Plan [Member] 2023 Restructuring Plan Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Stock issued under incentive programs (in shares) Share-Based Compensation Stock Issued Under Incentive Program Number of shares issued in incentive program. Year One Year One [Member] Year One Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Sanofi Sanofi [Member] Sanofi Federal, state, and local, income tax expense (benefit), continuing operations Federal, State, and Local, Income Tax Expense (Benefit), Continuing Operations Outstanding and Unvested, beginning balance (in usd per share) Outstanding and Unvested, ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value All Executive Categories All Executive Categories [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Preferred stock, par value per share (in usd per share) Preferred Stock, Par or Stated Value Per Share Plan Name [Domain] Plan Name [Domain] Outstanding, beginning balance (in usd per share) Outstanding, ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Collaborative Arrangement [Abstract] Collaborative Arrangement Milestones amortization Milestone Amortization [Member] Milestone Amortization Schedule of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Pfizer Pfizer [Member] Pfizer Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Debt Disclosure [Abstract] Debt Disclosure [Abstract] Royalties Royalty [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Segment Reporting Segment Reporting [Text Block] Marketable Securities Investment in Debt and Equity Securities and Other Trading Assets [Text Block] Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Canada Advanced Purchase Agreement Canada Advanced Purchase Agreement [Member] Canada Advanced Purchase Agreement Effect of exchange rate on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Annual milestone payments Annual Milestone Collaboration Payments Annual Milestone Collaboration Payments Remaining term, outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Tranche Axis [Domain] Tranche Axis [Domain] Tranche Axis [Domain] Facility and other research and development expenses Research and Development Expense, Facility And Other Research And Development Expenses Research and Development Expense, Facility And Other Research And Development Expenses 5.00% Convertible Senior Notes due 2027 Five Point Zero Convertible Senior Notes Due 2027 [Member] Five Point Zero Convertible Senior Notes Due 2027 Total convertible notes payable Convertible Debt, Fair Value Disclosures Shares exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Firm purchase commitment loss Inventory, Firm Purchase Commitment, Loss Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Sale of stock, number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Exercise Price Award Exercise Price Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Investing Activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Segment Reporting [Line Items] Segment Reporting [Line Items] Authorized amount Share Repurchase Program, Authorized, Amount Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Debt securities due in 2026 Debt Securities, Available-for-Sale, Excluding Accrued Interest, Due In 2026 Debt Securities, Available-for-Sale, Excluding Accrued Interest, Due In 2026 Compensation expense: Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Debt securities due in 2027 Debt Securities, Available-for-Sale, Excluding Accrued Interest, Due In 2027 Debt Securities, Available-for-Sale, Excluding Accrued Interest, Due In 2027 Europe Europe [Member] Debt securities due in 2028 Debt Securities, Available-for-Sale, Excluding Accrued Interest, Due In 2028 Debt Securities, Available-for-Sale, Excluding Accrued Interest, Due In 2028 Accounts receivable Accounts Receivable, after Allowance for Credit Loss Long-Term Debt Debt Disclosure [Text Block] Deductions Contract With Customer, Liability, Deductions Contract With Customer, Liability, Deductions Schedule of Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Supplier finance programs Research and Development Expense, Supplier Finance Program Research and Development Expense, Supplier Finance Program Beginning balance Ending balance Restructuring Reserve Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Secured Debt Secured Debt [Member] Total expenses Costs and Expenses Adoption Date Trading Arrangement Adoption Date Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders’ deficit Balance beginning Balance ending Equity, Attributable to Parent Restructuring Type [Axis] Restructuring Type [Axis] ASSETS Assets [Abstract] Development milestone payments Proceeds Development, Development Milestone Collaboration Payments Proceeds Development, Development Milestone Collaboration Payments Adjuvant Products Thereafter Adjuvant Products Thereafter [Member] Adjuvant Products Thereafter Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Milestones Milestone [Member] Milestone Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Insider Trading Policies and Procedures [Line Items] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Selling, general, and administrative Selling, general, and administrative expense Selling, General and Administrative Expense Database lock of an Existing Phase 2/3 clinical trial Database lock of an Existing Phase 2/3 clinical trial [Member] Database lock of an Existing Phase 2/3 clinical trial Type of Restructuring [Domain] Type of Restructuring [Domain] Government-backed securities Government Backed Securities [Member] Represents the information pertaining to government backed securities. Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Anti-dilutive securities excluded from calculations of diluted net income (loss) per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of business segments Number of Operating Segments Restricted stock units Restricted Stock Units (RSUs) [Member] Schedule of Goodwill Goodwill [Table Text Block] Entity Central Index Key Entity Central Index Key All Adjustments to Compensation All Adjustments to Compensation [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash used in operating activities Net cash provided by (used in) operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Development, tech transfer, launch, and sales milestone payments Proceeds Development, Development And Sales Milestone Collaboration Payments Proceeds Development, Development And Sales Milestone Collaboration Payments Stockholders' deficit: Equity, Attributable to Parent [Abstract] Income Statement [Abstract] Income Statement [Abstract] Document Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Direct other vaccine development programs Other Vaccine Development Programs [Member] Other Vaccine Development Programs Restructuring Plan [Domain] Restructuring Plan [Domain] Non-current finance lease liabilities Finance Lease, Liability, Noncurrent Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Assumptions Used in Estimation of Fair Value of Stock Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table Text Block] Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate City Area Code City Area Code Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Support services Support Services [Member] Support Services All Individuals All Individuals [Member] Employee and benefit expenses Research and Development Expense, Employee And Benefit Expenses Research and Development Expense, Employee And Benefit Expenses Name Forgone Recovery, Individual Name Unrecognized compensation expense, recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Per Share Weighted- Average Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] 5.00% Convertible notes due 2027 Five Point Zero Convertible Notes Due 2027 [Member] Five Point Zero Convertible Notes Due 2027 Statement [Line Items] Statement [Line Items] Research and development expenses: Research and Development Expense [Abstract] Total assets Assets Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Convertible Debt Convertible Debt [Member] Settlement Agreement Settlement Agreement [Member] Settlement Agreement Maximum developmental and sales milestone payments Collaboration Agreement, Maximum Developmental And Sales Milestone Payments Collaboration Agreement, Maximum Developmental And Sales Milestone Payments Right-of-use asset, net Lease, Right-Of-Use Asset Lease, Right-Of-Use Asset Range of Black-Scholes fair values of ESPP shares granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Interest expense Interest Expense, Nonoperating Schedule of Stock Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Licensed COVID-19 products and royalty payments Licensed COVID-19 Products And Royalty Payments [Member] Licensed COVID-19 Products And Royalty Payments Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Licensing, royalties, and other Licensing, Royalties, and Other [Member] Licensing, Royalties, and Other Organization and Business Nature of Operations [Text Block] PEO PEO [Member] Convertible Senior Notes Convertible Senior Notes [Member] Convertible Senior Notes Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Total stock-based compensation expense Share-Based Payment Arrangement, Expense Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, number of positions Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Marketable securities Marketable Securities, Current Other non-current liabilities Other Liabilities, Noncurrent Goodwill Beginning balance Ending balance Goodwill Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Takeda Takeda Arrangement [Member] Takeda Arrangement Restricted stock units granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Accumulated Deficit Retained Earnings [Member] Money market funds Money Market Funds [Member] Restricted stock units forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares outstanding (in shares) Balance beginning (in shares) Balance ending (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Corporate debt securities Corporate Debt Securities [Member] Diluted (in usd per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Total Shareholder Return Amount Total Shareholder Return Amount Accounts receivable, prepaid expenses, and other assets Increase (Decrease) in Prepaid Expense and Other Assets Liabilities Liabilities, Fair Value Disclosure [Abstract] Unrecongnized consideration Collaboration Agreement Unrecongnized Consideration Collaboration Agreement Unrecongnized Consideration Interest on convertible notes Interest on Convertible Debt, Net of Tax Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Tranche Axis [Axis] Tranche Axis [Axis] Tranche Axis Notice period for contract termination Notice Period For Contract Termination Notice Period For Contract Termination Supply sales Supply Sales [Member] Supply Sales Research and development Research and Development Expense Reconciliation of net income (loss) to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Sanofi Transition Services Sanofi Transition Services [Member] Sanofi Transition Services Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Financing Activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Financial Instruments [Domain] Financial Instruments [Domain] Working capital Working Capital Working Capital Summary of the Activity within the Accrued Severance and Employee Benefits Liability Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Proceeds from assets held for sale Proceeds from Sale, Property, Held-for-Sale Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Inventory Inventory Disclosure [Text Block] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Goodwill Intangible Asset and Goodwill [Text Block] Underlying Securities Award Underlying Securities Amount Revenue Revenue from Contract with Customer [Text Block] Canceled (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Inventory Increase (Decrease) in Inventories Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Segment Reporting [Table] Segment Reporting [Table] Shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Subscription rate cap Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Sale of Stock [Axis] Sale of Stock [Axis] Reportable Segment Reportable Segment [Member] Reportable Segment Direct COVID-19 Vaccine COVID-19 Vaccine [Member] COVID-19 Vaccine Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Income (loss) from operations Operating Income (Loss) Current Fiscal Year End Date Current Fiscal Year End Date CIC Product-Related Launch Milestones CIC Product-Related Launch Milestones [Member] CIC Product-Related Launch Milestones Obligated purchase price of raw materials Obligated Purchase Price of Raw Materials Obligated Purchase Price of Raw Materials Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Total long-lived assets Long-Lived Asset, Excluding Financial Instrument, Customer Relationship, Mortgage Servicing Right, Deferred Policy Acquisition Cost, and Deferred Tax Asset, Amount 2015 Plan Two Thousand Fifteen Stock Incentive Plan [Member] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Gavi Settlement Agreement Gavi Settlement Agreement [Member] Gavi Settlement Agreement Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Option and Appreciation Rights Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Impairment of long-lived assets Asset, Impairment Loss Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Upfront fee Upfront Fee [Member] Upfront Fee Finished goods Inventory, Finished Goods, Gross Treasury stock (in shares) Treasury Stock, Common, Shares Sales milestone payments Proceeds Development, Sales Milestone Collaboration Payments Proceeds Development, Sales Milestone Collaboration Payments Equity Components [Axis] Equity Components [Axis] Product and Service [Domain] Product and Service [Domain] Cash paid for income taxes, net of refunds received Income Tax Paid, after Refund Received Additions Contract With Customer, Liability, Additions Contract With Customer, Liability, Additions Australian APA Australian APA [Member] Australian APA Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Entity Interactive Data Current Entity Interactive Data Current Current portion of finance lease liabilities Finance Lease, Liability, Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Supplier Finance Program [Domain] Supplier Finance Program [Domain] Entity Small Business Entity Small Business Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Unamortized debt issuance costs Debt Instrument, Unamortized Discount Termination Date Trading Arrangement Termination Date August 2023 Sales Agreement August 2023 Sales Agreement [Member] August 2023 Sales Agreement Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Compensate services Collaboration Agreement Compensate Services Collaboration Agreement Compensate Services MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Corporate debt securities Cash And Cash Equivalents, Including Corporate Debt Securities Cash And Cash Equivalents, Including Corporate Debt Securities Other current liabilities Other Liabilities, Current Term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other non-current assets Other Assets, Noncurrent Document Type Document Type Fair value: Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 4.625% Convertible Senior Notes due 2031 Four Point Six Two Five Convertible Senior Notes Due 2031 [Member] Four Point Six Two Five Convertible Senior Notes Due 2031 Accrued expenses Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Aggregate intrinsic value, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Deferred revenue Deferred Revenue Increase (Decrease) [Abstract] Deferred Revenue Increase (Decrease) Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Exit fee percentage Debt Instrument, Exit Fee, Percentage Debt Instrument, Exit Fee, Percentage Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Deferred revenue Noncurrent deferred revenue Contract with Customer, Liability, Noncurrent Canada CANADA Semi-finished goods Inventory, Work in Process, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Income (loss) before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Supplier Finance Program [Axis] Supplier Finance Program [Axis] Commitments and contingencies (Note 15) Commitments and Contingencies Total revenue Revenues Revenue Revenues Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Accounts payable, accrued expenses, and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Goodwill [Roll Forward] Goodwill [Roll Forward] Counterparty Name [Axis] Counterparty Name [Axis] LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities and Equity [Abstract] Remaining term, exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term Inventory Total inventory Inventory, Net Equity Award [Domain] Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Fair Value Measurements Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Agency securities US Government Agencies Debt Securities [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term PEO Name PEO Name Geographical [Axis] Geographical [Axis] Deferred revenue Deferred revenue, beginning balance Deferred revenue, ending balance Contract with Customer, Liability Other segment income (expense) Segment Reporting, Other Segment Item, Amount Variable rate floor rate Debt Instrument, Variable Rate Floor Debt Instrument, Variable Rate Floor Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Total interest expense on long-term debt Interest Expense, Debt Cash payments Payments for Restructuring Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, cash equivalents, and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Restricted cash Restricted cash, current Restricted Cash and Cash Equivalent, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument [Axis] Debt Instrument [Axis] Non-cash stock-based compensation Share-Based Payment Arrangement, Noncash Expense Prepayment Year [Domain] Prepayment Year [Domain] Prepayment Year [Domain] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] ESPP Employee Stock [Member] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Basic (in usd per share) Earnings Per Share, Basic Raw materials Inventory, Raw Materials, Gross Deferred revenue Deferred Revenue Deferred revenue Current deferred revenue Contract with Customer, Liability, Current Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Tranche 3 Tranche 3 [Member] Tranche 3 Cost of sales Cost of Revenue Award Type [Axis] Award Type [Axis] First Four Adjuvant Products First Four Adjuvant Products [Member] First Four Adjuvant Products Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Restructuring and Related Activities [Abstract] Cost reimbursements Cost Reimbursements [Member] Cost Reimbursements Product and Service [Axis] Product and Service [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Number of reporting units Goodwill, Reporting Unit, Number Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Amount funded at closing Proceeds from Issuance of Secured Debt Common Stock Common Stock [Member] Treasury securities Debt Securities, Available-for-Sale Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Employee Severance Employee Severance [Member] Litigation settlement, expense Litigation Settlement, Fee Expense Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Interest Interest Expense, Debt, Excluding Amortization Currency translation adjustments Goodwill, Foreign Currency Translation, Gain (Loss) Equity Awards Adjustments Equity Awards Adjustments [Member] Year Two Year Two [Member] Year Two Collaboration, License, and Supply Agreements Collaborative Arrangement Disclosure [Text Block] Total liabilities and stockholders’ deficit Liabilities and Equity Stock options Share-Based Payment Arrangement, Option [Member] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table] Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Asset Class [Axis] Asset Class [Axis] Total Other Restructuring charge Restructuring Charges Plan Name [Axis] Plan Name [Axis] Foreign currency transaction gain (loss) Translation Adjustment Functional to Reporting Currency, Gain (Loss), Reclassified to Earnings, Net of Tax Unrestricted cash at least Debt Instrument, Covenant, Minimum Cash Balance Debt Instrument, Covenant, Minimum Cash Balance Inventory Disclosure [Abstract] Tabular List, Table Tabular List [Table Text Block] Restricted cash Restricted cash, non-current Restricted Cash and Cash Equivalent, Noncurrent Additional paid-in capital Additional Paid in Capital Royalty period Royalty Period Royalty Period Development and sales milestone payments, term Proceeds Development, Development And Sales Milestone Collaboration Payments, Term Proceeds Development, Development And Sales Milestone Collaboration Payments, Term Other income, net Other Nonoperating Income (Expense) Tranche 2 Tranche 2 [Member] Tranche 2 Name Awards Close in Time to MNPI Disclosures, Individual Name Entity Address, Country Entity Address, Country Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Aggregate intrinsic value, outstanding (less than) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Restricted stock units forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Upfront payment Collaboration Agreement Upfront Payment Collaboration Agreement Upfront Payment Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Pfizer Inc Pfizer Inc [Member] Pfizer Inc CIC Product-Related Development Milestones CIC Product-Related Development Milestones [Member] CIC Product-Related Development Milestones Preferred stock, $0.01 par value, 2,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025 Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Rest of the world Rest of the World [Member] Rest of the World Class of Stock [Domain] Class of Stock [Domain] Other partners Other Partners [Member] Other Partners Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Cash interest payments, net of amounts capitalized Interest Paid, Excluding Capitalized Interest, Operating Activity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Advanced payment paid Contract With Customer, Advance Payment Refund, Credited Against Outstanding Invoices Contract With Customer, Advance Payment Refund, Credited Against Outstanding Invoices Credit Facility [Axis] Credit Facility [Axis] Restructuring Restructuring and Related Activities Disclosure [Text Block] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Total cash equivalents and marketable securities Assets, Fair Value Disclosure Name Measure Name Income Taxes Income Tax Disclosure [Text Block] Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Other items, net Other Noncash Income (Expense) Tranche 1 Tranche 1 [Member] Tranche 1 Debt Instrument [Line Items] Debt Instrument [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalent Royalty revenue period Debt Instrument, Covenant, Royalty Revenue, Period Debt Instrument, Covenant, Royalty Revenue, Period Company Selected Measure Amount Company Selected Measure Amount Proceeds development, tech transfer, launch, and sales milestone collaboration payment, term Proceeds Development, Tech Transfer, Launch, And Sales Milestone Collaboration Payment, Term Proceeds Development, Tech Transfer, Launch, And Sales Milestone Collaboration Payment, Term Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Minimum grant price, percent of common stock fair value Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Exercise Price Minimum Percent The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price. Upfront payments Upfront Payments Upfront Payments Cash, Cash Equivalents, and Restricted Cash Cash and Cash Equivalents Disclosure [Text Block] Cumulative catch up adjustment Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract Nuvaxovid Nuvaxovid [Member] Nuvaxovid Current assets: Assets, Current [Abstract] Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Restricted stock units vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Stockholders' Equity Subsidiary, Sale of Stock [Line Items] Income tax expense Income Tax Expense (Benefit) Award Timing Method Award Timing Method [Text Block] Product and Service, Other Product and Service, Other [Member] Net decrease in cash, cash equivalents, and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Claim related to performance obligation Loss Contingency, Accrual, Current Volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Credit Agreement due 2031 Credit Agreement [Member] Credit Agreement 2023 Inducement Plan Two Thousand Twenty Three Stock Inducement Plan [Member] Two Thousand Twenty Three Stock Inducement Plan Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Statement [Table] Statement [Table] Liquidity and Going Concern Liquidity and Going Concern [Policy Text Block] Liquidity and Going Concern Restatement Determination Date: Restatement Determination Date [Axis] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Interest income Investment Income, Interest Shares exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Number of disease areas Number Of Disease Areas Number Of Disease Areas Litigation settlement, amount awarded to other party Litigation Settlement, Amount Awarded to Other Party Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Provision for excess and obsolete inventory Provision For Excess And Obsolete Inventory Provision For Excess And Obsolete Inventory Revenue: Revenues [Abstract] Schedule of Share Based Compensation Restricted Stock Awards Activity Schedule Of Share Based Compensation Restricted Stock Awards Activity [Table Text Block] Schedule Of Share Based Compensation Restricted Stock Awards Activity Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block]